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Q  How do hyaluronic acid  
and corticosteroid injections 
compare for knee OA relief?
 Inconsistent evidence shows 
 a small amount of pain relief early 
(one week to 3 months) with corticosteroid 
(CS) injections and an equally small im-
provement in pain relief and function later 
(3 to 12 months) with hyaluronic acid (HA) 
injections (strength of recommendation 
[SOR]: B, meta-analysis of a randomized 
controlled trial [RCT] and inconsistent 
RCTs). 
Guidelines state that CS injections can 
be considered for symptomatic knee os-
teoarthritis (OA), but that insufficient evi-
dence exists to recommend HA injections 
(SOR: B, evidence-based guidelines).
ONLINE
EXCLUSIVE
Evidence summary
A 2015 network meta-analysis of 137 RCTs 
with 33,243 patients (ages 45-76 years) with 
knee OA compared the effectiveness of a vari-
ety of treatments including intra-articular CS 
and HA.1 At 3 months, the effect on pain was 
not significantly different between the CS and 
HA groups (12 trials; effect size [ES]=0.02; 95% 
confidence interval [CI], -0.12 to 0.17). How-
ever, a small but significant improvement in 
function was noted (scoring system not de-
fined) at 3 months favoring HA (ES=0.24; 95% 
CI, 0.06-0.43; number of trials not specified). 
At 3 and 6 months, HA improves pain,  
but not function, more than CS
Another meta-analysis published in 2015 ex-
amined the effectiveness of intra-articular CS 
and HA in 7 RCTs with 583 patients with knee 
OA.2 All 7 trials were included in the network 
meta-analysis and discussed separately to 
evaluate different time points.
Pain at one month wasn’t significantly 
different using a visual analog score (VAS) of 
one to 100 (4 trials; 245 patients; mean differ-
ence [MD]=1.66 points; 95% CI, -0.90 to 4.23). 
At 3 and 6 months, the HA group reported 
significantly reduced pain compared with 
the CS group (3 months: 3 trials; 320 patients; 
MD=12.58 points; 95% CI, -17.76 to -7.40; 
6 months: 5 trials; 411 patients; MD=9.01 
points; 95% CI, -12.62 to -5.40). There were 
no significant differences in function out-
comes (Index of severity for OA of the knee 
by Lequesne et al; The Knee Society Clinical 
Rating System), maximum flexion, or adverse 
events.
Triamcinolone improves pain, function,  
but not for long
A 2016 double-blind RCT of 110 patients with 
knee OA compared intra-articular HA and 
triamcinolone, assessing pain and function 
at intervals between 24 hours and 6 months.3 
Patients in the HA group received a single 
injection of 6 mL hylan G-F 20 (Synvisc); pa-
tients in the CS group received 1 mL of tri-
amcinolone acetonide 40 mg and 5 mL of 1% 
lidocaine with epinephrine. 
The CS group reported significantly less 
pain (VAS score 1 to 100) at 24 hours than the 
HA group (24 points vs 36 points; P=.002); re-
lief lasted as long as one week (14 points vs 
23 points; P=.018). After the first week, no dif-
ference was seen in pain between groups for 
as long as 6 months. 
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Function, assessed by a modified West-
ern Ontario and McMaster Universities Os-
teoarthritis Index (WOMAC 1 to 100; higher 
score indicates worse pain, stiffness, and 
function) showed a significant improvement 
with CS at 2 weeks (25 points vs 31 points; 
P=.03), but no difference at any other time 
point up to 6 months.
HA (mostly) improves pain, function  
more than betamethasone
A 2015 RCT of 200 patients with knee 
OA compared the effectiveness of intra- 
articular HA and betamethasone.4 Evaluators 
were blinded and assessments were made at 
3, 6, 9, and 12 months. The HA group received 
2.5 mL of 1% HA (Suprahyal); the CS group 
received betamethasone dipropionate 5 mg 
plus betamethasone sodium phosphate 2 mg 
in 1 mL. 
The CS group had significantly less pain 
(VAS 1 to 10) at 3 months compared with the 
HA group (2.2 points vs 3.1 points; P=.004), 
but the HA group had less pain at all other 
time points (6 months: 3.9 points vs 
2.4 points; P=.0001; 9 months: 5.5 points vs 
3.6 points; P=.0001; 12 months: 6 points vs 
4.1 points; P=.0001). 
The WOMAC function subscores (0 to 
68; lower indicates more function) were sig-
nificantly better at all follow-up points in 
the HA group compared with the CS group 
(3 months: 19 vs 25; P=.0001; 6 months: 
17 vs 29; P=.0001; 9 months: 25 vs 42; P=.0001; 
12 months: 28 vs 42; P=.0001).4 
Recommendations
The American Academy of Orthopaedic Sur-
geons 2013 work group couldn’t recommend 
for or against using intra-articular CS for pa-
tients with symptomatic knee OA based on 
inconclusive evidence.5 They also couldn’t 
recommend using HA (SOR: strong). 
The National Institute for Health and 
Care Excellence (NICE) stated in 2008 that 
intra-articular CS injections should be con-
sidered as an adjunct to core treatments for 
the relief of moderate to severe pain in peo-
ple with OA.6 In 2014, NICE recommended 
against offering intra-articular HA injections 
for managing OA. 
The US Veterans Administration and 
Department of Defense have issued guide-
lines stating that clinicians may consider 
intra-articular CS injections for patients with 
symptomatic knee OA (US Preventive Ser-
vices Task Force [USPSTF] Grade B).7 They 
report insufficient evidence to recommend 
for or against the use of intra-articular HA 
with the caveat that HA may be considered 
for patients who don’t respond adequately to 
nonpharmacologic measures and who have 
an inadequate response, intolerable adverse 
events, or contraindications to other pharma-
cologic therapies (USPSTF Grade I).             JFP
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